All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

267

Reset

267 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • spartalizumabPDR001Phase 21 trial

    Novartis · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

  • SPVN20Phase 21 trial

    SparingVision · Retinitis Pigmentosa (RP), Rod Cone Dystrophy

  • SRP-1001ARO-DUX4Phase 21 trial

    Sarepta Therapeutics, Inc. · Muscular Dystrophy, Facioscapulohumeral

  • SRP-1003ARO-DM1Phase 21 trial

    Sarepta Therapeutics, Inc. · Myotonic Dystrophy 1

  • ST-920Phase 21 trial

    Sangamo Therapeutics · Fabry Disease

  • SXR1096Phase 21 trial

    Sixera Pharma · Netherton Syndrome

  • TAR-0520Phase 21 trial

    Tarian Pharma · Hand and Foot Syndrome

  • TGRX-814Phase 21 trial

    Shenzhen TargetRx Co., Ltd. · Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia

  • TISA-818-InjPhase 21 trial

    EnliTISA (Shanghai) Pharmaceutical Co., Ltd. · Acute Respiratory Distress Syndrome (ARDS)

  • TJO-087Phase 21 trial

    Taejoon Pharmaceutical Co., Ltd. · Dry Eye Syndrome (DES)

  • TRYP-0082Phase 21 trial

    TRYP Therapeutics · Irritable Bowel Syndrome

  • TSRA-196Phase 21 trial

    Tessera Therapeutics, Inc. · Alpha-1 Antitrypsin Deficiency (AATD)

  • TuspetinibHM43239Phase 21 trial

    Aptose Biosciences Inc. · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML

  • VG801Phase 21 trial

    VeonGen Therapeutics GmbH · Retinal Dystrophy Due to Biallelic ABCA4 Mutations, Stargardt Disease 1

  • VP-001Phase 21 trial

    PYC Therapeutics · Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease

  • VTRU200Phase 21 trial

    Vitruviae · Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome

  • WVE-006Phase 21 trial

    Wave Life Sciences USA, Inc. · Alpha-1 Antitrypsin Deficiency

NewerPage 6 of 6

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.